EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan was associated with a 68.3% reduction in proteinuria at 26 weeks vs. placebo. Of patients treated ...

In this video from the Macula Society meeting, Sunir J. Garg, MD, FACS, FASRS, of the retina service at Wills Eye Hospital, ...

The Food and Drug Administration (FDA) has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC ...

Pegcetacoplan (Empaveli) reduced proteinuria and helped stabilize kidney function in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (MPGN). The C3 and C3b ...

Hemotransfusion in treatment of anemia, 3D illustration showing two populations of red blood cells, small hypochromic red blood cells and normal. A small lymphocyte is drawn for size comparison ...

A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of ...

STOCKHOLM -- Atrophic age-related macular degeneration control appeared better with pegcetacoplan (Syfovre) as compared with avacincaptad pegol (Izervay) in a propensity-matched cross-trial comparison ...

After posting mixed late-stage data last fall and securing FDA support to include midstage data in its approval application for pegcetacoplan in geographic atrophy (GA), Apellis has been awaiting one ...

Robust and clinically meaningful benefits observed across all three key markers of disease – 68% reduction in proteinuria, stabilisation of kidney function, and substantial clearance of C3 deposits.

Patients with paroxysmal nocturnal hemoglobinuria (PNH) who had suboptimal response to eculizumab can switch to pegcetacoplan for a cost-effective alternative, according to. acost analysis.